Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Condition:   Follicular Lymphoma (FL) Interventions:   Drug: Epcoritamab;   Drug: Rituximab;   Drug: Lenalidomide Sponsors:   AbbVie;   Genmab Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2022 Category: Research Source Type: clinical trials